1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT

Denise Albano,1 Thomas Bilfinger,1 Barbara Nemesure2 1Department of Surgery, Health Sciences Center, Stony Brook Medicine, Stony Brook, NY, USA; 2Department of Family, Population and Preventive Medicine, Health Sciences Center, Stony Brook Medicine, Stony Brook, NY, USA Background: Lobectomy has tra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Albano D, Bilfinger T, Nemesure B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	SBRT Lobectomy Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c708ba98bdb240ee93b7cc3227dc9206
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c708ba98bdb240ee93b7cc3227dc9206
record_format	dspace
spelling	oai:doaj.org-article:c708ba98bdb240ee93b7cc3227dc92062021-12-02T07:28:37Z1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT1179-2728https://doaj.org/article/c708ba98bdb240ee93b7cc3227dc92062018-08-01T00:00:00Zhttps://www.dovepress.com/1--3--and-5-year-survival-among-early-stage-lung-cancer-patients-treat-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Denise Albano,1 Thomas Bilfinger,1 Barbara Nemesure2 1Department of Surgery, Health Sciences Center, Stony Brook Medicine, Stony Brook, NY, USA; 2Department of Family, Population and Preventive Medicine, Health Sciences Center, Stony Brook Medicine, Stony Brook, NY, USA Background: Lobectomy has traditionally been recommended for fit patients diagnosed with early-stage non-small-cell lung cancer (NSCLC). Recently, however, stereotactic body radiotherapy (SBRT) has been introduced as an alternative treatment option. The purpose of this investigation is to compare survival outcomes for individuals with stage I/II NSCLC treated with lobectomy vs SBRT. Methods: This retrospective study included 191 patients (100 surgery, 91 SBRT) identified through the Lung Cancer Evaluation Center, Stony Brook, NY, between 2008 and 2012. Survival and recurrence rates were compared using Kaplan–Meier curves, log-rank tests, and Cox proportional hazard models to adjust for possible confounders. A subset of cases was propensity-matched to address potential differences in health status between groups. Results: 1-, 3-, and 5-year survival outcomes were significantly better among patients undergoing lobectomy vs SBRT. Survival rates at 3 years were 92.8% and 59.0% (p<0.001) in the 2 groups, respectively. Propensity-matched analyses indicated similar findings. Recurrence rates were likewise lower among patients undergoing surgery (7.1% vs 21.0%, p<0.01 at 3 years); however, statistical significance was not maintained in the propensity-matched analysis. Conclusion: These findings add to a growing evidence base supporting the use of lobectomy vs SBRT in the treatment of lung cancer among healthy, early-stage NSCLC patients. Keywords: SBRT, lobectomy, survivalAlbano DBilfinger TNemesure BDove Medical PressarticleSBRTLobectomySurvivalNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 9, Pp 65-71 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	SBRT Lobectomy Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	SBRT Lobectomy Survival Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Albano D Bilfinger T Nemesure B 1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
description	Denise Albano,1 Thomas Bilfinger,1 Barbara Nemesure2 1Department of Surgery, Health Sciences Center, Stony Brook Medicine, Stony Brook, NY, USA; 2Department of Family, Population and Preventive Medicine, Health Sciences Center, Stony Brook Medicine, Stony Brook, NY, USA Background: Lobectomy has traditionally been recommended for fit patients diagnosed with early-stage non-small-cell lung cancer (NSCLC). Recently, however, stereotactic body radiotherapy (SBRT) has been introduced as an alternative treatment option. The purpose of this investigation is to compare survival outcomes for individuals with stage I/II NSCLC treated with lobectomy vs SBRT. Methods: This retrospective study included 191 patients (100 surgery, 91 SBRT) identified through the Lung Cancer Evaluation Center, Stony Brook, NY, between 2008 and 2012. Survival and recurrence rates were compared using Kaplan–Meier curves, log-rank tests, and Cox proportional hazard models to adjust for possible confounders. A subset of cases was propensity-matched to address potential differences in health status between groups. Results: 1-, 3-, and 5-year survival outcomes were significantly better among patients undergoing lobectomy vs SBRT. Survival rates at 3 years were 92.8% and 59.0% (p<0.001) in the 2 groups, respectively. Propensity-matched analyses indicated similar findings. Recurrence rates were likewise lower among patients undergoing surgery (7.1% vs 21.0%, p<0.01 at 3 years); however, statistical significance was not maintained in the propensity-matched analysis. Conclusion: These findings add to a growing evidence base supporting the use of lobectomy vs SBRT in the treatment of lung cancer among healthy, early-stage NSCLC patients. Keywords: SBRT, lobectomy, survival
format	article
author	Albano D Bilfinger T Nemesure B
author_facet	Albano D Bilfinger T Nemesure B
author_sort	Albano D
title	1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
title_short	1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
title_full	1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
title_fullStr	1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
title_full_unstemmed	1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
title_sort	1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs sbrt
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/c708ba98bdb240ee93b7cc3227dc9206
work_keys_str_mv	AT albanod 13and5yearsurvivalamongearlystagelungcancerpatientstreatedwithlobectomyvssbrt AT bilfingert 13and5yearsurvivalamongearlystagelungcancerpatientstreatedwithlobectomyvssbrt AT nemesureb 13and5yearsurvivalamongearlystagelungcancerpatientstreatedwithlobectomyvssbrt
_version_	1718399425676574720

1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT

Ejemplares similares